Yanzuo Chen

Dr. Yanzuo Chen

East China University of Science and Technology
orcid

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 February 2021 in Journal of Personalized Medicine
Verified
Journal Article
Open access
PDF file
DHDong Huang
Dong Huang
LSLingna Sun
Lingna Sun
Leaf HuangLeaf Huang
Leaf Huang
Yanzuo ChenYanzuo Chen
Yanzuo Chen
The use of nanomedicine for antitumor therapy has been extensively investigated for a long time. Enhanced permeability and retention (EPR) effect-mediated drug delivery is currently regarded as an effective way to bring drugs to tumors, especially macromolecular drugs and drug-loaded pharmaceutical nanocarriers. However, a disordered vessel network, and occluded or embolized tumor blood vessels seriously limit the EPR effect. To augment the EPR effect and improve curative effects, in this review, we focused on the perspective of tumor blood vessels, and analyzed the relationship among abnormal angiogenesis, abnormal vascular structure, irregular blood flow, extensive permeability of tumor vessels, and the EPR effect. In this commentary, nanoparticles including liposomes, micelles, and polymers extravasate through the tumor vasculature, which are based on modulating tumor vessels, to increase the EPR effect, thereby increasing their therapeutic effect.

1 April 2021 in Biomaterials
Verified
Journal Article
Closed access
LSLingna Sun
Lingna Sun
MFMingrui Fan
Mingrui Fan
DHDong Huang
Dong Huang
BLBingqin Li
Bingqin Li
RXRuoting Xu
Ruoting Xu
Yanzuo ChenYanzuo Chen
Yanzuo Chen

1 July 2015 in International Journal of Pharmaceutics
Verified
Journal Article
Closed access
Yanzuo ChenYanzuo Chen
Yanzuo Chen
WZWei Zhang
Wei Zhang
YHYukun Huang
Yukun Huang
FGFeng Gao
Feng Gao
XSXianyi Sha
Xianyi Sha
XFXiaoling Fang
Xiaoling Fang

12 April 2019 in Molecular Pharmaceutics
Verified
Journal Article
Closed access
XHXiaqin Huang
Xiaqin Huang
JWJunru Wu
Junru Wu
MHMuye He
Muye He
XHXinyu Hou
Xinyu Hou
YWYan Wang
Yan Wang
Yanzuo ChenYanzuo Chen
Yanzuo Chen

20 December 2021 in Biomaterials Science
Verified
Journal Article
Closed access
PDF file
KJKeqin Ji
Keqin Ji
MFMingrui Fan
Mingrui Fan
DHDong Huang
Dong Huang
LSLingna Sun
Lingna Sun
BLBingqin Li
Bingqin Li
Yanzuo ChenYanzuo Chen
Yanzuo Chen
Liver fibrosis therapy remains limited due to the inefficiency of drug delivery and inflammation induced by Kupffer cells. In this study, an exosome–liposome hybrid drug delivery system (LIEV) was developed to increase the efficacy of clodronate (CLD)-inhibition of Kupffer cells and to effectively deliver nintedanib (NIN) to liver fibroblasts to ensure enhanced anti-fibrosis therapy. CLD and NIN co-loaded LIEV (CLD/NIN@LIEV) exerted non-specific inhibition of phagocytosis by Kupffer cells, reduced inflammatory cytokines, and showed homologous homing properties mediated by fibroblast-derived exosomes, thereby achieving superior antifibrotic effects in a CCl4-induced fibrosis mouse model by inhibiting the proliferation of fibroblasts. Furthermore, the inhibited Kupffer cells regenerated within 10 days after dosage withdrawal. Unlike carrier-free NIN treatment, CLD/NIN@LIEV induced a marked decrease in liver enzymes, indicating improved safety and anti-fibrosis efficacy. These results indicate its great potential for treatment with the combined anti-fibrosis agent and Kupffer cell inhibition strategies to enhance the liver fibrosis therapy.

17 January 2019 in ACS Nano
Verified
Journal Article
Closed access
Yanzuo ChenYanzuo Chen
Yanzuo Chen
WSWantong Song
Wantong Song
LSLimei Shen
Limei Shen
NQNasha Qiu
Nasha Qiu
MHMengying Hu
Mengying Hu
Leaf HuangLeaf Huang
Leaf Huang